Empagliflozin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Empagliflozin: SGLT2 inhibitor → classic stiff person syndrome
One-Sentence Summary
Empagliflozin is an SGLT2 inhibitor (a drug that lowers blood glucose by reducing glucose reabsorption in the kidney) marketed in Canada. The TxGNN model predicts it may be effective for classic stiff person syndrome, with a score of 0.9906. There are currently no clinical trials and no publications supporting this direction, so it is a model-generated hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | classic stiff person syndrome |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 8 of 8) |
| Number of DINs | 8 (marketed: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for empagliflozin is not available in the data compiled for this report. Based on general knowledge, empagliflozin is an SGLT2 inhibitor that lowers renal glucose reabsorption.
Classic stiff person syndrome is an autoimmune neurological disorder characterized by anti-GAD65 antibodies and impaired GABAergic signaling. One plausible link is a shared association with autoimmune diabetes (GAD65 autoimmunity). However, this is an inference from the model’s data patterns, not a demonstrated pharmacological mechanism. No evidence shows that SGLT2 inhibition affects the neurological features of this disease.
The prediction should therefore be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02443945 | JARDIANCE | Not recorded | Not recorded |
| 02443937 | JARDIANCE | Not recorded | Not recorded |
| 02456591 | SYNJARDY | Not recorded | Not recorded |
| 02456575 | SYNJARDY | Not recorded | Not recorded |
| 02456605 | SYNJARDY | Not recorded | Not recorded |
Eight licences are listed in the data, all currently valid. Only the first five are shown here.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interactions; those shown in the data are mostly of Moderate severity, with a few Minor. Examples include:
- Moderate: phenylephrine, acebutolol, acetazolamide, formoterol, pseudoephedrine, nifedipine, epinephrine, ethinylestradiol, hydrocortisone, salbutamol, ethanol, furosemide, fosinopril
- Minor: topical hydrocortisone, topical alclometasone
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score, with no clinical trials or publications addressing stiff person syndrome. The mechanistic link is speculative, so the evidence level is L5.
To proceed, the following is needed:
- Any clinical or preclinical study directly examining SGLT2 inhibition in stiff person syndrome
- Mechanism-of-action data for empagliflozin
- Package insert warnings and contraindications from Health Canada, for safety screening
- Review of the safety profile in patients with autoimmune neurological disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.